Benitec Biopharma Inc represents values of innovation, scientific excellence, and patient-centricity. With a strong corporate philosophy focused on transforming patient lives, Benitec Biopharma is committed to developing cutting-edge therapies using its proprietary gene-silencing technology, ddRNAi. The company's dedication to scientific advancement and rigorous research enables them to address unmet medical needs in various therapeutic areas, including genetic diseases and viral infections. Benitec Biopharma emphasizes collaboration, integrity, and transparency in its pursuit of breakthrough treatments, aiming to provide hope and improved outcomes for patients worldwide. Through its relentless commitment to scientific progress, Benitec Biopharma aims to revolutionize the field of biopharmaceuticals and contribute to the betterment of global healthcare.

Benitec Biopharma Inc is primarily present in the United States, with headquarters located in Hayward, California. The company focuses on developing and commercializing RNA-based therapeutics for various diseases. While Benitec Biopharma Inc primarily operates in the United States, it also has a global presence through collaborations and partnerships. By leveraging its innovative gene silencing technology, the company aims to provide effective treatments for debilitating diseases worldwide.

Benitec Biopharma Inc, a leading biotechnology company, has achieved significant milestones throughout its journey. The company has successfully developed and patented a groundbreaking gene-silencing technology known as ddRNAi. By harnessing this innovative platform, Benitec Biopharma Inc has made remarkable strides in advancing therapeutic treatments for various diseases and conditions. Over the years, the company has demonstrated exceptional progress in preclinical and clinical studies, showcasing the potential of its novel approach. Moreover, Benitec Biopharma Inc has actively collaborated with renowned institutions and established strategic partnerships, thereby enhancing its research capabilities and broadening its reach in the biopharmaceutical industry. These achievements highlight the pioneering contributions of Benitec Biopharma Inc in revolutionizing gene-based therapies.

Benitec Biopharma Inc., founded in 1995, is a clinical-stage biotechnology company headquartered in Australia. With a primary focus on gene silencing technology, Benitec aims to treat a wide range of genetic diseases through its proprietary DNA-directed RNA interference (ddRNAi) platform. The company has developed several key therapeutic candidates, including BB-301 for oculopharyngeal muscular dystrophy and BB-103 for hepatitis B, demonstrating the potential of its innovative approach. Benitec Biopharma Inc. has entered into strategic partnerships and collaborations to accelerate its research and development efforts, strengthening its position in the biopharmaceutical industry. Continuously committed to advancing novel therapies, Benitec stands at the forefront of genetic medicine discoveries.

The main competitors of Benitec Biopharma Inc in the market are companies like Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and uniQure N.V. These companies also operate in the biopharmaceutical industry and offer similar gene therapy and RNAi-based treatments. Benitec Biopharma Inc competes with these companies in terms of developing innovative therapies, securing patents, attracting investors, and gaining market share.

Benitec Biopharma Inc is primarily active in the biopharmaceutical industry.

The business model of Benitec Biopharma Inc revolves around developing and commercializing genetic medicines. Benitec utilizes its proprietary gene-silencing technology, called ddRNAi, to target and inhibit the expression of specific disease-causing genes. Through strategic partnerships and collaborations, Benitec aims to advance its pipeline of therapeutic candidates across various disease areas, including ophthalmology, hepatitis B, and oncology. By leveraging its expertise in RNA interference, Benitec strives to bring innovative treatments to patients, with the ultimate goal of improving health outcomes and addressing unmet medical needs.

Benitec Biopharma KGV ir -0,08.

Benitec Biopharma KUV ir 0.

AlleAktien kvalitātes vērtējums Benitec Biopharma ir 3/10.

Pašreiz nevar aprēķināt apgrozījumu Benitec Biopharma.

gaidāmā Benitec Biopharma peļņa ir -145,70 milj. USD.

Benitec Biopharma Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA-based therapies. The company is headquartered in Australia and is listed on the NASDAQ stock exchange. The business model of Benitec Biopharma involves utilizing innovative technologies to develop RNA-based therapies for severe and rare diseases. The company focuses on gene therapy and RNA interference technology. The company has three divisions: research and development, clinical development, and commercial marketing. In the research and development department, scientists work on developing new RNA-based therapeutics. The clinical development department focuses on testing and successfully advancing the technology in clinical trials. The company has the capability to conduct clinical trials at any stage of development. The final division is responsible for marketing and selling therapeutics that are already in the clinical phase or have already been approved. Benitec Biopharma has a strong network of distribution partners who assist in the marketing and sale of these products. An important product being developed by Benitec Biopharma is BB-301. BB-301 is an RNA-based therapeutic used in the treatment of the rare genetic skin disease Epidermolysis Bullosa (EB). The disease often affects children and can be life-threatening. The medication is currently in the clinical phase and has shown positive results in Phase 1b. Another important product is BB-102. This RNA-based therapeutic is currently in the preclinical phase and aims to treat Hemophilia B. Hemophilia B is a bleeding disorder caused by a deficiency in blood clotting factor IX. The medication has the potential to significantly improve the lives of patients with Hemophilia B. In summary, Benitec Biopharma Inc. plays a crucial role in the development of innovative RNA-based therapies for the treatment of severe and rare diseases. With the help of its research and development department, clinical development, and commercial marketing, the company will be able to successfully bring its products to the market and have a positive impact on patients.

Benitec Biopharma izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Benitec Biopharma vai uzņēmums nedod dividendes.

Benitec Biopharma ISIN ir US08205P1003.

Benitec Biopharma WKN ir 722783.

Benitec Biopharma simbols ir BNTC.

Pēdējo 12 mēnešu laikā Benitec Biopharma maksāja dividendes 0,04 USD apmērā. Tas atbilst aptuveni 0,51 % dividendes ražībai. Nākamajos 12 mēnešos Benitec Biopharma plāno maksāt dividendes 0 USD apmērā.

Benitec Biopharma pašreizējā dividendu rentabilitāte ir 0,51 %.

Benitec Biopharma maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Benitec Biopharma pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Benitec Biopharma tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Benitec Biopharma apmērā 0,003 USD, kas tika izmaksāta 8.06.2018., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.06.2018..

Pēdējās dividendes izmaksa notika 8.06.2018..

Gadā 2023, Benitec Biopharma izmaksāja 0 USD dividendes.

Benitec Biopharma dividendes tiek izmaksātas USD.